Overview

Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations

Status:
Completed

Trial end date:
2014-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study is to establish Bioequivalence (BE) of 2 different formulations of the 2 mg/24 hr (10 cm^2) Rotigotine transdermal patches in Chinese subjects.

Phase:

Phase 1

Details

Lead Sponsor:

UCB Pharma SA

Treatments:

N 0437
Rotigotine